SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
about
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingRing finger protein 149 is an E3 ubiquitin ligase active on wild-type v-Raf murine sarcoma viral oncogene homolog B1 (BRAF)Looking at cerebellar malformations through text-mined interactomes of mice and humansThe developing story of Sprouty and cancer.Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.ERK and JNK activation is essential for oncogenic transformation by v-Rel.ErbB2 stabilizes epidermal growth factor receptor (EGFR) expression via Erk and Sprouty2 in extracellular matrix-detached cellsConstitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing FieldSprouty-2 regulates oncogenic K-ras in lung development and tumorigenesisInduction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant CellsAggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulationFibrosis in the lens. Sprouty regulation of TGFβ-signaling prevents lens EMT leading to cataract.Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines.ERK MAP kinase in G cell cycle progression and cancer.A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathyTargeted therapy for BRAFV600E malignant astrocytoma.Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL.BRAF(E600) in benign and malignant human tumours.The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways.DNA microarray analyses of melanoma gene expression: a decade in the mines.MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous MelanomaIdentification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.Tumor adaptation and resistance to RAF inhibitors.Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.SPROUTY2 is a β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer.Mechanisms of Drug Resistance in Melanoma.Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.Strong negative feedback from Erk to Raf confers robustness to MAPK signalling.Distinct MHC gene expression patterns during progression of melanoma.Sprouty2-mediated inhibition of fibroblast growth factor signaling is modulated by the protein kinase DYRK1A.Confirmation of a BRAF mutation-associated gene expression signature in melanoma.Sprouty2 regulates growth and differentiation of human neuroblastoma cells through RET tyrosine kinase.SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150.Genes with relevance for early to late progression of colon carcinoma based on combined genomic and transcriptomic information from the same patients.Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation.Targeting oncogenic BRAF in human cancer.
P2860
Q21133611-F3699FE5-DFE9-4F30-88C8-AD7728D333CDQ28588647-86602B79-C17F-49FE-BCED-EC71402E68BFQ33515271-2612F2DD-A95E-4B75-9674-38F0010DFF31Q33962853-B97713D2-AC8A-409A-89D9-333194EDAFE9Q34225871-0E427AB6-2B08-4570-82DA-CA9D7BDCF5BEQ34351185-B93CD8A8-B96A-4700-B1BA-A4A7E741C79CQ34452774-4D37C6A3-4200-44D0-9EB1-0EC1664C6C43Q34622439-35D345E6-410C-4200-AE6A-354C20BB61D9Q34996130-534DBB07-2FC8-426F-9BCC-FE37144702AAQ35677359-9AB3D014-61A6-4C7E-A11A-88624BE0D9AFQ35811459-EDE617F4-AD1A-4077-8F6A-A33968AFDB93Q36050683-076DA3B1-F56B-4C40-A3C3-841D75C26230Q36303720-A04CE82B-F452-4619-87BB-C88F1ED5BB6EQ36454937-6722EDF0-E6E7-4840-B9C2-75A8E55DC304Q36519437-DD828EB4-D407-4D0D-99EC-72DF3E54FB24Q36695721-BF83CC6E-EC31-41AD-8F28-0C1C7E81CDADQ36800148-347BA1A2-D456-4972-9FB8-B91F6D8FA15CQ36897123-4477CEC7-8554-4912-992F-EBC4CD7A1576Q36921234-FEB2A24B-BF9B-4D2C-94BA-62DB81E097D3Q36954946-755E7C3F-E69A-4DE4-82F5-C9612164E2E9Q36970643-476C2125-0E49-476C-9253-92A85FBAA1DFQ36973484-1AD634B7-829E-4A37-BE57-A72D952185F2Q37042015-6CDC21F1-E092-46E2-9441-A3A09F9CB03AQ37112466-40D00BD2-D514-4E62-8B40-BF9758A24F5AQ37745182-C5198F42-30B9-48EF-9799-6EA82D5479AEQ37753517-B2F9269D-B113-4E7D-9DFD-5DE4036C54D4Q38160738-93B0F652-B180-49E7-9482-9A40B30F3527Q38329529-3BC11FB1-D8EF-40A4-A3EB-F192678F187FQ39159176-040DBD62-6A85-4967-BD33-BCC57AE4BE6BQ39169776-435E2CEB-91BE-4947-ABBE-622896B49B04Q39173195-35282646-4DE5-4757-8CF1-157448995BC9Q39536250-01EB3B0E-A5D4-400B-A81D-6C9FFDB636E7Q39782582-0932DE54-1120-44A7-9B3F-3DD68F1C13E2Q39954149-3C050E98-F85C-411D-ACBF-9E214B4C6540Q40129786-9CDD4791-EA1D-486B-9B65-F152043844D0Q40153841-5CB47CFD-B90A-4D44-A3C4-5FB25B32EE19Q40444666-F3B53AE4-F94A-474C-A1AA-CAEA52552659Q40475980-787B289D-BFB4-40E8-BA35-B35EC0E0A133Q41822622-5067F548-4E61-4F9C-9A5E-8C92870B1221Q42020468-D7DDA479-B197-4905-97ED-1F3FB2B8A163
P2860
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
SPRY2 is an inhibitor of the r ...... but not with the V599E mutant.
@en
type
label
SPRY2 is an inhibitor of the r ...... but not with the V599E mutant.
@en
prefLabel
SPRY2 is an inhibitor of the r ...... but not with the V599E mutant.
@en
P2093
P1433
P1476
SPRY2 is an inhibitor of the r ...... but not with the V599E mutant.
@en
P2093
Barbara L Weber
Dimitra Tsavachidou
Galene Athanasiadis
Jonathan D Licht
Shuixing Li
P304
P356
10.1158/0008-5472.CAN-04-1669
P407
P577
2004-08-01T00:00:00Z